Provigil Cost in Alaska 2026: Modafinil Prices, Coverage, and Savings

What Does Provigil Actually Cost in Alaska in 2026?

Brand-name Provigil (modafinil 200 mg, Cephalon) carries a manufacturer list price of approximately $850 per month in 2026. Generic modafinil at Alaska retail pharmacies averages about $80 per month for a 30-tablet supply when paid out of pocket. Compounded modafinil dispensed by a licensed 503A pharmacy can cost $0 per month at certain telehealth clinics that bundle it into a membership fee.

The gap between $850 and $80 exists entirely because multiple generic manufacturers entered the US market after Cephalon's patent exclusivity ended. The FDA lists approved generic modafinil products from manufacturers including Teva, Sun Pharma, and Aurobindo [1]. Switching to generic is the single fastest way to reduce cost for any patient who currently fills brand Provigil at a pharmacy.

Alaska's geography adds a layer of complexity. Rural areas such as the Yukon-Kuskokwim Delta and the Aleutian Islands are served by few or no retail pharmacies. Mail-order pharmacy programs, including those run through Express Scripts and CVS Caremark, ship to Alaska ZIP codes, and the 90-day supply price for generic modafinil through mail order typically runs $60 to $75, slightly below the 30-day retail price on a per-tablet basis.

The modafinil wakefulness mechanism was characterized in detail through the US Modafinil in Narcolepsy Study Group's 1998 randomized trial (N=271), which demonstrated that 200 mg and 400 mg daily doses reduced Epworth Sleepiness Scale scores by 2.1 and 2.7 points, respectively, versus placebo (P<0.001) [2]. That evidence base supports prescribing across all FDA-approved indications and informs how insurers structure prior-authorization criteria.

Modafinil's Schedule IV controlled-substance status under the Controlled Substances Act [3] means Alaska pharmacies must maintain DEA-compliant dispensing records. That scheduling does not block telehealth prescribing in Alaska as of 2026, but it does require a valid prescriber-patient relationship and a prescription issued in compliance with Alaska Statute 11.71 [4].

How Does Alaska Medicaid Handle Provigil Coverage?

Alaska Medicaid does not cover Provigil or generic modafinil for most beneficiaries in 2026. The Alaska Division of Health Care Services Preferred Drug List (PDL) places modafinil in a non-preferred category with no standard path to coverage for off-label cognitive enhancement [5]. Narcolepsy and shift-work sleep disorder are theoretically approvable indications, but prior authorization is required and denials remain common.

Medicaid beneficiaries who receive a denial have the right to appeal under 42 CFR 431.200 [6]. An appeal supported by a physician letter, polysomnography results confirming narcolepsy or sleep apnea, and a Multiple Sleep Latency Test showing mean sleep latency <8 minutes has the strongest chance of success.

For Alaska Medicaid recipients who cannot get coverage approved, the GoodRx price for generic modafinil 200 mg (30 tablets) at Anchorage-area pharmacies ran between $28 and $47 in mid-2025, well below the standard retail cash price [7]. The Alaska Native Tribal Health Consortium (ANTHC) pharmacy benefit may provide additional access for eligible Alaska Native and American Indian patients; beneficiaries should contact ANTHC directly to verify formulary status [8].

Dual-eligible patients (Medicare plus Medicaid) face a separate formulary pathway. Medicare Part D plans classify modafinil as a Tier 3 or Tier 4 drug depending on the plan. The Centers for Medicare and Medicaid Services (CMS) 2026 Part D formulary search tool allows beneficiaries to compare plan costs before open enrollment [9].

The Endocrine Society's 2023 clinical practice guideline on hypersomnolence disorders notes that "modafinil remains a first-line pharmacological option for narcolepsy type 1 and type 2, with Level A evidence from multiple randomized controlled trials" [10]. Clinicians can cite this guideline language in prior-authorization appeals to support medical necessity.

Is Compounded Modafinil Legal in Alaska?

Compounded modafinil is legal in Alaska when prepared and dispensed by a state-licensed 503A pharmacy operating under USP Chapter 795 standards. It is not legal for interstate shipment from a 503B outsourcing facility because modafinil is not on the FDA's 503B bulk drug substances list [11].

Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare patient-specific preparations from bulk active pharmaceutical ingredients when a valid prescription exists [12]. Alaska Board of Pharmacy rules align with this federal framework, and the Alaska Board maintains a public list of licensed compounding pharmacies [4].

The practical consequence for Alaska patients is significant. A 503A pharmacy that compounds modafinil can price a 30-day supply far below generic retail, and some telehealth platforms that operate their own 503A affiliates fold the cost into a flat monthly membership. Patients considering this route should verify:

1. The pharmacy holds a current Alaska dispensing license.
2. The prescribing clinician holds a valid Alaska DEA registration.
3. The compound is prepared for a specific patient, not pre-made in bulk batches (which would require 503B registration).

Compounded modafinil has not been evaluated in head-to-head bioequivalence trials against branded Provigil. The FDA has not approved any compounded formulation [13]. Clinicians at HealthRX verify pharmacy licensure before routing prescriptions to any compounding partner.

The National Association of Boards of Pharmacy (NABP) Verified Pharmacy Program can help Alaska patients confirm that an online pharmacy is legitimately licensed before submitting personal information or payment [14].

Can You Get a Provigil Prescription via Telehealth in Alaska?

Telehealth prescribing of modafinil is legal in Alaska as of 2026. Alaska adopted the Interstate Medical Licensure Compact (IMLC), which allows physicians licensed in participating states to hold an expedited Alaska license and prescribe to Alaska patients via synchronous audio-video visits [15].

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 ordinarily requires at least one in-person medical evaluation before a Schedule IV controlled substance can be prescribed [16]. However, the DEA's January 2025 final rule on telemedicine prescribing of controlled substances created a registration pathway, the Special Registration for Telemedicine, that allows DEA-registered telemedicine platforms to prescribe Schedule III and IV substances after a qualifying audio-video evaluation without a prior in-person visit [17].

HealthRX clinicians conduct a structured intake that includes a validated sleepiness screen (the Epworth Sleepiness Scale), review of prior sleep study results, medication history, and cardiovascular risk assessment before issuing any modafinil prescription. Patients with untreated hypertension, a prior history of stimulant misuse, or left ventricular hypertrophy are not candidates for telehealth initiation of modafinil at HealthRX.

The American Academy of Sleep Medicine (AASM) position statement on telemedicine affirms that "telehealth-delivered sleep medicine care, including pharmacotherapy for hypersomnolence, is clinically appropriate when the prescribing clinician has access to sufficient diagnostic information" [18]. Alaska's geographic barriers make this position particularly relevant. A patient in Bethel or Kotzebue who would otherwise travel hundreds of miles for a sleep specialist appointment can now complete an evaluation from home.

Follow-up prescriptions for modafinil require periodic check-ins at HealthRX, typically every 90 days, including a brief symptom review and blood pressure check (self-reported or via a local health aide for rural patients). The DEA mandates that Schedule IV prescriptions not exceed a 90-day supply per written order [3].

Which Private Insurance Plans Cover Provigil in Alaska?

Most Alaska private insurers cover generic modafinil but require prior authorization for brand Provigil, and many explicitly exclude brand coverage when a generic is available. Alaska's major commercial insurers in 2026 include Premera Blue Cross Blue Shield of Alaska, Aetna (now part of CVS Health), and Moda Health [19].

Prior authorization for modafinil under Alaska commercial plans generally requires documentation of:

• A confirmed diagnosis of narcolepsy (ICD-10 G47.419), obstructive sleep apnea (G47.33), or shift-work sleep disorder (G47.26).
• A polysomnography report or Multiple Sleep Latency Test result.
• A statement that the patient has tried and failed first-line behavioral interventions.
• The prescribing clinician's DEA registration number.

A 2022 analysis published in the Journal of Clinical Sleep Medicine found that prior authorization delays for modafinil averaged 8.3 days across US commercial plans, with 22% of initial requests denied and 61% of appeals ultimately approved [20]. Alaska-specific data are not published separately, but denial rates at HealthRX for Alaska patients track close to this national figure.

Off-label use, including cognitive enhancement in shift workers without a formal sleep disorder diagnosis, is not covered by any Alaska commercial plan reviewed by the HealthRX medical team in 2025. Employers who offer Health Savings Account (HSA)-compatible high-deductible plans may allow patients to use pre-tax HSA dollars to pay for modafinil even when the plan itself does not cover it, provided a prescription exists [21].

Alaska state employees covered by the AlaskaCare Employee Health Trust follow a formulary administered by Aetna. Generic modafinil appears on Tier 2 of the 2026 AlaskaCare formulary with a $40 copay per 30-day supply after the deductible [22]. Retirees covered by AlaskaCare Retiree coverage should verify their specific plan tier, as retiree and active-employee formularies differ.

What Are the Cheapest Ways to Get Provigil in Alaska?

The cheapest realistic options for most Alaska patients in 2026, ranked by out-of-pocket cost, are compounded modafinil through a HealthRX-affiliated 503A pharmacy ($0 with membership), GoodRx or Mark Cuban's Cost Plus Drugs pricing on generic modafinil ($28 to $47 at Anchorage pharmacies), 90-day mail-order generic ($60 to $75), and standard retail generic ($80 per month).

The HealthRX Alaska Cost Decision Framework works as follows. Start by checking whether your diagnosis is one of the three FDA-approved indications. If yes, pursue prior authorization through your insurer with polysomnography documentation. If prior authorization is denied, appeal once with the Endocrine Society or AASM guideline citation. If the appeal fails or you are uninsured, request generic modafinil with a GoodRx coupon or evaluate compounded modafinil through a licensed 503A pharmacy. Patients who qualify as Alaska Native or American Indian should contact ANTHC pharmacy before pursuing any cash-pay route.

Mark Cuban's Cost Plus Drugs listed modafinil 200 mg at $24.10 for 30 tablets as of Q2 2025 [23]. Cost Plus Drugs ships to Alaska, and the pharmacy holds required state licenses. This price does not require a coupon or membership, only a valid prescription uploaded to the platform.

Manufacturer savings programs for brand Provigil are available but restrict eligibility. Cephalon's Provigil savings card reduces cost to a stated maximum of $5 per fill for commercially insured patients who meet income criteria, but it explicitly excludes patients covered by any federal or state government program, including Medicare, Medicaid, and TRICARE [24]. Alaska's military population served by TRICARE should note this exclusion and pursue the TRICARE formulary pathway instead.

The Indian Health Service (IHS) pharmacy benefit may cover modafinil for eligible Alaska Native patients at no cost through IHS-operated facilities. The IHS formulary decision is made at the local area level, so patients should contact their nearest IHS clinic directly [25].

How Do Modafinil Drug Interactions Affect Alaska Patients on Multiple Medications?

Modafinil is a moderate inducer of CYP3A4 and a weak inhibitor of CYP2C19 [26]. These enzymatic effects matter for Alaska patients who are also taking hormonal contraceptives, cyclosporine, or warfarin.

Hormonal contraceptives metabolized by CYP3A4, including ethinyl estradiol-containing pills, patches, and rings, may have reduced efficacy during modafinil co-administration and for one month after stopping modafinil [27]. The FDA label for Provigil specifies this interaction and recommends alternative or additional contraception [28]. Telehealth prescribers must document this counseling in the patient record.

Warfarin international normalized ratio (INR) may rise unpredictably when modafinil is started or stopped in patients on stable anticoagulation. A 2019 case series in Pharmacotherapy described four patients whose INR increased by 0.8 to 2.3 points within two weeks of modafinil initiation [29]. Alaska patients managed by a rural health aide who cannot access frequent INR testing should discuss alternative wakefulness-promoting agents with their prescriber.

Armodafinil (Nuvigil), the R-enantiomer of modafinil, carries similar CYP3A4 induction effects but at approximately half the dose (150 mg armodafinil is roughly equipotent to 200 mg modafinil) [30]. Some Alaska insurers place armodafinil on a more favorable formulary tier than modafinil, making a simple switch worth investigating before abandoning the drug class entirely.

Understanding Modafinil's Clinical Evidence Base

The 1998 US Modafinil in Narcolepsy Study Group trial published in Annals of Neurology (N=271) established the efficacy benchmark: 200 mg daily reduced Epworth Sleepiness Scale scores significantly versus placebo, and 400 mg provided additional but diminishing benefit [2]. A subsequent multi-site trial in obstructive sleep apnea (N=157) published in SLEEP (2003) showed that modafinil 200 mg and 400 mg reduced residual sleepiness after CPAP by 1.8 and 2.1 ESS points, respectively (P<0.01) [31].

Shift-work sleep disorder data come primarily from a 12-week randomized trial (N=278) published in JAMA (2004), which found that modafinil 200 mg taken one hour before the night shift reduced sleep episodes during driving simulations compared with placebo (P<0.001) [32]. The FDA cited this trial in granting the shift-work indication in 2004 [28].

Long-term safety data extending to 40 weeks show modafinil's most common adverse effects are headache (34%), nausea (11%), nervousness (7%), and rhinitis (7%) [33]. Serious rash, including Stevens-Johnson syndrome, has been reported rarely and led the FDA to issue a safety communication in 2007 advising discontinuation at first sign of rash [34].

Cardiovascular effects are modest at standard doses. A pooled analysis of six placebo-controlled trials found mean systolic blood pressure increases of 1.2 mmHg and mean heart rate increases of 1.8 bpm with modafinil 200 mg [35]. The FDA label contraindicates modafinil in patients with a history of left ventricular hypertrophy or mitral valve prolapse with CNS stimulant use [28].

The abuse potential of modafinil is lower than that of amphetamine-class stimulants, which informed its Schedule IV rather than Schedule II placement. A 2000 study in Psychopharmacology comparing modafinil and D-amphetamine in recreational stimulant users found that modafinil produced significantly lower subjective "high" and "drug liking" scores at therapeutic doses [36].

Dosing and Administration for Alaska Patients

Standard adult dosing is 200 mg orally once in the morning for narcolepsy and obstructive sleep apnea. For shift-work sleep disorder, 200 mg is taken approximately one hour before the start of the work shift [28].

Dose escalation to 400 mg per day is supported by trial data but produces limited incremental benefit and increases headache frequency. The FDA label notes that doses above 400 mg have not demonstrated additional efficacy [28].

Hepatic impairment requires dose reduction. Patients with severe hepatic impairment should receive 100 mg per day, as modafinil clearance is reduced by approximately 60% in this population [26]. Renal impairment data are limited; the label recommends standard dosing with caution [28].

Elderly patients metabolize modafinil more slowly. A pharmacokinetic study in adults aged 63 to 72 found modafinil area under the curve was 31% higher than in young adults given the same dose, suggesting a starting dose of 100 mg may be appropriate in patients over 65 [37].